Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
AddLife AB's, reg. no 556995-8126, ("AddLife") acquisition of Vision Ophthalmology Group GmbH ("VOG") on 8 April 2021 and acquisition of Healthcare 21 Group ("HC21") on 12 April 2021 were in part financed by newly issued Class B shares in AddLife (the "issues in kind"). As a result of the issues in kind, the number of Class B shares in AddLife in April 2021 have increased with 7,951,958 Class B shares and 7,951,958 votes.
After the Issues in kind the total number of shares as per 30 April 2021 amounts to 122,450,250, corresponding to in total 163,986,474 votes. 4,615,136 of these shares are Class A shares, representing 46,151,360 votes and 117, 835,114 are Class B shares, representing 117,835,114 votes.
AddLifes' share capital has, as a result of the issues in kind, changed from SEK 58,309,339.55 to SEK 62,358,949.47 while the par value of the share of approximately SEK 0.51 remains unchanged.
For further information, please contact:
Kristina Willgård, CEO and Group CEO, AddLife AB, kristina.willgard@add.life,+46 (0)705 10 12 23
Martin Almgren, CFO, AddLife AB, martin.almgren@add.life,+46 (0)702 28 15 45
AddLife is a European, independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors. AddLife has about 1,800 employees in some 70 operating subsidiaries. The Group currently has net sales of around SEK 7 billion. AddLife shares are listed on Nasdaq Stockholm.
This information is information that AddLife AB is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons set out above, on 30 April 2021 at 10:00 am CET.